Must Know Business and Marketing Strategy for China's Pharmaceutical Market
Posted on: Thursday, 18 September 2008, 00:00 CDT
Research and Markets (http://www.researchandmarkets.com/research/50622d/business_and_marke) has announced the addition of the "Business and Marketing Strategy for China's Pharmaceutical Market" report to their offering.
Do you know what it takes to succeed in today's ever evolving China pharmaceutical market? What are profitable foreign and domestic drug companies doing in China to maximize growth and increase sales? What are the current market trends and how can you apply these effectively for your company? China is the ninth largest pharmaceutical market in the world, worth approximately $20 billion. Buy a webcast CD today, before it's too late, to learn more about marketing and selling effectively and developing your high-return business strategy. This 90-minute session will include a 60-minute presentation, followed by 30 minutes of Q&A.
This webcast is designed for pharmaceutical professionals in regulatory affairs, business development, international sales and marketing, and anyone who wants to be current on Chinese drug issues
Key Topics Covered: - Overview of China Healthcare - China Pharmaceutical Market Industry Overview - What Foreign Drug Companies Are Doing in China: --Manufacturing --Selling --Clinical Studies --R+D - Domestic Chinese Companies --Will Chinese Generics be Entering the Western Markets? --Are There New Drugs to License? --Traditional Chinese Medicine's Growth - Examples of Successful Chinese Companies - M&A in Drug Area - Best Way to Distribute Drugs in China - The OTC market - Drug Registration Overview - Pricing and Reimbursement - Key New Regulatory Issues - Future Trends and Things to Look Out For
For more information visit http://www.researchandmarkets.com/research/50622d/business_and_marke
Source: Business Wire
Related Articles
- Establishment of IOTA Pharmaceuticals, a New Fragment-Based Drug Discovery Company, With Research Centres in Cambridge (UK), Amsterdam (The Netherlands), and Ahmedabad (India)
- Pharmaceutical Companies Expanding Post-Market Drug Safety Initiatives to Prevent Adverse Reactions, Finds PricewaterhouseCoopers Study
- Mutual Pharmaceutical Company Files Counter Suit Against Adams Respiratory Therapeutics
- Independent Expert Confirms View That Adams Has No Legal Basis for Pursuing Legal Action Against Mutual Pharmaceutical Company for Its Guaifenesin Extended-Release Tablets, 600 Mg and 1200 Mg
- United Research Laboratories/Mutual Pharmaceutical Company Formally Notifies Adams Respiratory Therapeutics of Its ANDA Filing for Guaifenesin Extended-Release Tablets, 600 Mg and 1200 Mg
- Research and Markets: Sales for the Pharmaceutical Company Takeda Increased By 7% to Reach 935,213 Million Yen
- Research and Markets: Key Pharmaceutical Subsidiaries Can Be Seen Inside the Dainippon Pharmaceutical Company Intelligence Report
- China is Expected to Become the Fifth Largest Drug Market in the World By 2010 - a Comprehensive Guidebook for Foreign Pharmaceutical Companies
- Research and Markets: Five Year Sales Forecasts for the Pharmaceutical Company - Sanofi-Aventis
- KV Pharmaceutical Company to Market New Generic Drugs in U.S. Via Exclusive Deal With Gedeon Richter
 |
 |
User Comments (0)
RSS Feeds